Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13532967 | 0.89 | PARP1 (0.38) | PARP1SLC6A2GABRA1GABRG2GABRB3 | |
| SCHEMBL19682340 | 0.85 | PARP1 (0.45) | PARP1SLC6A2HTR2CSLC6A4KCNH2 | |
| SCHEMBL26462964 | 0.85 | PARP1 (0.45) | PARP1SLC6A2HTR2CSLC6A4KCNH2 | |
| SCHEMBL24469475 | 0.85 | PARP1 (0.49) | PARP1SLC6A2HTR2CLMNACYP1A2 | |
| SCHEMBL3364105 | 0.85 | PARP1 (0.49) | PARP1SLC6A2GABRA1GABRG2GABRB3 | |
| SCHEMBL14031976 | 0.84 | GABRA1 (0.41) | PARP1SLC6A2GABRA1GABRG2GABRB3 | |
| Hydrochloric Acid SCHEMBL29042929 | 0.84 | PARP1 (0.47) | PARP1SLC6A2LMNACYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL29042928 | 0.84 | PARP1 (0.47) | PARP1SLC6A2LMNACYP1A2CYP3A4 | |
| SCHEMBL13179976 | 0.82 | PARP1 (0.42) | PARP1SLC6A2HTR2CTSHRSLC6A4 | |
| SCHEMBL19121348 | 0.82 | PARP1 (0.42) | PARP1SLC6A2HTR2CTSHRSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | LIFEARC (GB) | 2024-06-27 | — | — | US | disclosed |
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | LIFEARC (GB) | 2024-06-27 | — | — | US | disclosed |
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2024112830-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11845715-B2 | — | — | 2023-12-19 | — | — | US | disclosed |
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | JAPAN TOBACCO INC. (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | JAPAN TOBACCO INC. (JP) | 2023-12-14 | — | — | US | disclosed |
| EP-3901147-B1 | ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023220741-A1 | ALPHA 4 BETA 7 INTEGRIN MODULATORS AND USES THEREOF | DICE MOLECULES SV, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7504402-B2 | Triazole derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase-1 | MERCK & CO., INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504411-B2 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-17 | — | — | US | disclosed |
| US-20080255118-A1 | Cyanopyrimidinones | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20070293496-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | OZAKI FUMIHIRO | 2007-12-20 | — | — | US | disclosed |
| US-7265108-B2 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| EP-1484327-B1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINE THEREOF | EISAI R&D MAN CO LTD (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | MAPT, HTT, PSEN1 | PARP1 43/4885SLC6A2 2624/4885GABRA1 3342/4885 |
| US-20070293496-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | XDH, NQO1, CYP1A1 | PARP1 755/4885SLC6A2 1216/4885GABRA1 3298/4885 |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | PARP1 73/4885SLC6A2 4533/4885GABRA1 4260/4885 |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | PARP1 1457/4885SLC6A2 4034/4885GABRA1 2292/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | PARP1 73/4885SLC6A2 4533/4885GABRA1 4260/4885 |
| US-11845715-B2 | — | NLRP3, PYCARD, NOD1 | PARP1 3601/4885SLC6A2 4307/4885GABRA1 3219/4885 |
| US-20240208934-A1 | ULK1/2 INHIBITORS AND THEIR USE THEREOF | ULK1, ULK2, ULK3 | PARP1 349/4885SLC6A2 4303/4885GABRA1 2388/4885 |
| US-20080255118-A1 | Cyanopyrimidinones | CACYBP, CHRM4, CHRNA4 | PARP1 1751/4885SLC6A2 768/4885GABRA1 330/4885 |
| US-20230399319-A1 | Acylsulfamide Compound and Pharmaceutical Use Therefor | NLRP3, NLRP1, NOD1 | PARP1 1089/4885SLC6A2 3161/4885GABRA1 2080/4885 |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | PARP1 2973/4885SLC6A2 2914/4885GABRA1 3387/4885 |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | PARP1 1457/4885SLC6A2 4034/4885GABRA1 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.